Clinical Trials Logo

Papilloma clinical trials

View clinical trials related to Papilloma.

Filter by:

NCT ID: NCT05677360 Recruiting - Clinical trials for Human Papilloma Virus (HPV) Vaccine

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

HPV MISTICS
Start date: January 9, 2023
Phase: N/A
Study type: Interventional

This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the intervention effect, and will explore implementation outcomes of the intervention.

NCT ID: NCT05669911 Active, not recruiting - Clinical trials for Human Papilloma Virus

Development of a Self-collection Device for Cervical Cancer Screening

Start date: August 28, 2022
Phase: N/A
Study type: Interventional

Evaluation of a novel self-collection device for cervical cancer screening.

NCT ID: NCT05640700 Recruiting - Clinical trials for Human Papilloma Virus

Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia

Start date: November 9, 2022
Phase:
Study type: Observational

In this study, the investigators will prospectively collect, analyze and integrate information regarding vaginal microbiome composition and HPV presence in women with cervical pathologies (high-grade CIN and CC) and controls, to construct a large dataset from patients with pre-cancerous cervical lesions and healthy women, to evaluate the personalized contribution of the vaginal microbiome to the CIN-CC sequence.

NCT ID: NCT05625308 Completed - Papilloma Clinical Trials

Effect of Natural Compounds on the Severity of HPV-induced Cervical Lesions

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

To test the efficacy of a newly-commercialized formula, 40 HPV-positive women displaying chronic cervicitis, mild dysplasia or moderate dysplasia. Women in the study group took one tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid for twelve weeks. Women in the control group received no treatment.

NCT ID: NCT05600283 Enrolling by invitation - Clinical trials for Human Papilloma Virus

Patient Self-sampling of HPV to Screen for Cervical Cancer

Start date: November 16, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to validate a patient self-sampling vaginal collection kit and laboratory testing for the detection of HPV (human papillomavirus) infection. Researchers will compare the laboratory results of self-collected vaginal swab samples to usual healthcare provider-collected cervical swab samples to determine the laboratory HPV testing accuracy of the self-collection swab.

NCT ID: NCT05582590 Not yet recruiting - Clinical trials for Head and Neck Cancer

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

Start date: March 31, 2025
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic HPV-related oropharyngeal cancers. Patients must have received at least one prior standard treatment regimen consisting of systemic immunotherapy and/or chemotherapy. The investigative agent is an autologous adoptive T-cell product derived from the patient's endogenous cytolytic T cells that are directed toward HPV-16 E6/E7, HPV-18 E6/E7 antigens, and a tumor-associated antigen (Survivin) by ex vivo exposure to an artificial antigen presenting cell to which HLA-A2 antigen-peptides have been fit within the pocket of an MHC class 1 molecule. Patients must express HLA-A*0201.

NCT ID: NCT05566106 Recruiting - Clinical trials for Human Papilloma Virus

Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV

Cohorte_HPV
Start date: September 22, 2022
Phase:
Study type: Observational

Human Papillomavirus (HPV) infection is the most common sexually transmitted infection in the world. It is currently estimated that 4.5% of all cancers worldwide are attributable to HPV, representing 630,000 new cases per year. HPV is responsible for more than 98% of pre-cancerous and cancerous lesions of the cervix and vagina and 88% of anal cancers. Although prevention of HPV infection has been available since 2007, there are approximately 3000 new cases of cervical cancer in France each year. Women benefit from organized screening for cervical cancer. HPV is also responsible for anal cancer in more than 90% of cases, mostly caused by HPV 16/18. Its incidence is lower with 1162 cases in women in 2018 but is increasing strongly (+88% in women since 1990). As with cervical cancer, there are precursors to anal cancer: high-grade intraepithelial lesions. Early diagnosis of these lesions could potentially reduce the incidence of anal cancer, but there are still few data in the literature. The prevalence of anal carriage in patients with a history of cervical dysplasia or cervical cancer is estimated in studies to be 20% with a risk of high grade anal lesions of 8%. The relative risk of developing anal cancer in women with a history of high-grade cervical lesions is about 5 per 100,000, 15 per 100,000 for those with a history of cervical cancer, and 42 and 48 per 100,000 respectively for women with HPV-induced pre-cancer and cancerous lesions of the vulva. The different means of cervico-vaginal screening: screening samples: HPV test, cytology, some biomarkers: double labelling p16/ki67, E6-E7 mRNA and clinical examination with or without colposcopy (examination of the cervix with a magnifying glass) are used at the gynecological level but also at the anal level with as examination: simple anuscopy and high resolution anuscopy. Some scientific societies have established surveillance algorithms for certain risk groups, but there are no clinical practice recommendations yet for women with a history of gynecological HPV-induced lesions. A proctology follow-up protocol for at-risk patients is proposed to patients based on cervico-vaginal surveillance recommendations and data in the literature, pending clinical practice guidelines. The frequency of these examinations depends on the patient's age and the existence of other risk factors for the development of anal HPV lesions. Depending on these elements, follow-up is proposed every 3 years, 5 years, or annually. The objective of this work is therefore to propose proctological surveillance to this population considered at risk, according to age, smear results and HPV test.

NCT ID: NCT05539274 Completed - Cervical Cancer Clinical Trials

Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus

Start date: July 1, 2019
Phase:
Study type: Observational

incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer

NCT ID: NCT05536674 Not yet recruiting - Clinical trials for HPV, Human Papillomavirus Viruses, Human Papilloma Virus Vaccine

SMS Reminders to Strengthen Demand for HPV Vaccination in Georgia

Start date: September 13, 2022
Phase: N/A
Study type: Interventional

It is possible that achieving adequate HPV vaccination coverage will allow cervical cancer to be virtually eliminated. This is a priority for Georgia, where the burden of mortality and morbidity from cervical cancer is high and the yearly prevalence of cervical cancer is 14.5 per 100,000 population. The objective of the intervention evaluated is to increase the uptake of the 1st dose of the HPV vaccination in Georgia. The intervention aims to achieve this by providing a SMS reminder informed by behavioural insights (BI) to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination, share information about the vaccine, and encourage them to book an appointment to receive the vaccination. Four different SMS messages will be compared to no SMS message. The evaluation will be a 5-arm randomised controlled trial (RCT) which aims to answer the research question: Does each of the designed BI-informed SMS reminders increase the uptake of the first dose of the HPV vaccination among eligible girls in Georgia, compared to no reminder? Our hypothesis is that SMS reminders will increase the uptake of HPV vaccination.

NCT ID: NCT05510830 Not yet recruiting - Cervical Cancer Clinical Trials

Diagnostic Cervical Conization for Persistent Infection or Integration of HPV

Start date: October 2022
Phase: N/A
Study type: Interventional

For the patients with cervical persistent infection or integration of HPV, we has designed a program to perform cervical conization for certain patients to earlier and better diagnose and cure the diseases of HPV infection and related cervical intraepithelial neoplasia/cancer.